



WHAT THE COMPANY DOES

Sahajanand Medical Technologies Limited is an Indian medical device company focused on the research, development, manufacturing, and commercialization of Class III and Class C/D cardiovascular intervention products, including drug-eluting stents, balloon catheters, TAVI systems, and structural heart occluders.

FINANCIALS, RS. CRORE

	FY24	CAGR
Revenue	902	—
Total debt	175	—

THE DOCUMENT'S OWN CASE, FOR AND AGAINST

RISKS IT DISCLOSES

- 1. The company is subject to extensive regulatory requirements across geographies, and any non-compliance or failure to maintain approvals could adversely impact operations. (p.20)
- 2. Manufacturing operations face operational risks including quality control issues, equipment failure, and capacity under-utilization. (p.22)
- 3. The company is dependent on third-party suppliers for raw materials and components, with top 10 suppliers contributing significantly to total purchases. (p.26)
- 4. A majority of revenues are derived from Vascular Intervention devices, specifically the single product Supraflex Cruz. (p.28)
- 5. Regulatory pricing uncertainty and price ceilings imposed by NPPA on medical devices in India could restrict margins and revenues. (p.29)

Both columns are the offer document's own words, not this page's assessment.

Analysed from the RHP at https://assets.ipopremium.in/images/ipo/sahajanand_medical_technologies_ltd_mainboard_rhp_1791630001.pdf by IPO Agent's proprietary AI-assisted extraction on 2026-10-12. Every extracted figure was string-matched back to the source document.
Information and data aggregation only. Not investment advice. No recommendation to apply or avoid is made or implied. Figures are reproduced from the offer document and may contain extraction errors. Verify against the source before acting.

Get every IPO decoded, free. One clear email per IPO, with the analysis, the GMP reality-check and the dates. Subscribe at ipoagent.kredfit.com